# TROPION-Lung15 (NCT06417814)

> A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06417814
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Metastatic Non-small Cell Lung Cancer
- Interventions: Dato-DXd; Osimertinib; Pemetrexed; Carboplatin; Cisplatin
- Enrollment: 744
- Primary outcome: Progression free Survival (PFS)

## Commentary we found

- Podcasts: 13
- YouTube: 9
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=tropion-lung15-nct06417814

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06417814", "email": "<work email>"}; the inbox owner confirms by the emailed link.